Product Description
Mechanisms of Action: N/A
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Navidea
Company Location: DUBLIN OH 43017
Company CEO: Michael S. Rosol
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Alzheimer Disease
Phase 2: Alzheimer Disease|Cognitive Dysfunction
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
APEX | N/A |
Enrolling by invitation |
Alzheimer Disease |
2028-06-01 |
|
ADNI4 | N/A |
Recruiting |
Cognitive Dysfunction|Alzheimer Disease |
2027-07-31 |
|
HEAD | P1 |
Recruiting |
Alzheimer Disease |
2027-05-31 |
|
ADiOSA | N/A |
Terminated |
Alzheimer Disease|Dementia, Vascular|Acute Respiratory Distress Syndrome|Conduct Disorder |
2019-12-12 |